Virology

Korea University College of Medicine Identifies Hantavirus in South Korea Using a New Rapid Test, Paving Way for Early Outbreak Control

Retrieved on: 
Thursday, February 29, 2024
Viral hemorrhagic fever, Virology, Hope, Branches of microbiology, Prevalence, Eisenmenger syndrome, Journal, Genomics, Issue 1, Shrew, Orthohantavirus, Research, DNA, Public, Vaccine

SEOUL, South Korea, Feb. 29, 2024 /PRNewswire/ -- Orthohantaviruses, highly transmissible zoonotic pathogens, are notorious for causing hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome in the Americas. With a significant impact on public health, they have been extensively researched for effective outbreak control and intervention strategies. Gyeonggi Province in South Korea has reported a significant number of HFRS cases, making it a critical area for epidemiological surveillance and understanding the genomic diversity of orthohantaviruses.

Key Points: 
  • With a significant impact on public health, they have been extensively researched for effective outbreak control and intervention strategies.
  • Notably, the study showcased the application of Flongle sequencing, an innovative, cost-efficient, and rapid method, for detecting HTNV genomes.
  • "We developed a rapid and sensitive on-site diagnostic using a nanopore-based Flongle chip with a reasonable cost of around $100.
  • Title of original paper: High-resolution phylogeographical surveillance of Hantaan orthohantavirus using rapid amplicon-based Flongle sequencing, Republic of Korea

HPV's Hidden Hand: New Study by Pusan National University Scientists Reveals Key Details in Head and Neck Cancer Microenvironment

Retrieved on: 
Wednesday, February 28, 2024
School, Neoplasm, Incidence, PKM2, Viral, Virology, Informatics, Assistant, Throat, Growth, Health informatics, Human papillomavirus infection, Branches of microbiology, Mouth, RNA, PKM, Tumor microenvironment, B cell, Ephrin, Patient, Glomus tumor, Journal, Tobacco, Medicine, Pusan National University, HPV, HNSCC, Head, Research, Nose, Cancer, EPHA2, Vaccine

BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat. HNSCC is typically associated with tobacco exposure, alcohol abuse, and viral infections. The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.

Key Points: 
  • BUSAN, South Korea, Feb. 28, 2024 /PRNewswire/ -- Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that affects the mucous membranes of the mouth, nose, and throat.
  • The links between human papillomavirus (HPV) infection status and the molecular characteristics of HNSCC are not clearly defined.
  • Therefore, the HPV infection could be considered a criterion for developing treatment strategies, thereby enabling precision medicine tailored to the patient's condition!
  • Title of original paper: Deciphering Head and Neck Cancer Microenvironment: Single–Cell and Spatial Transcriptomics Reveals Human Papillomavirus–Associated Differences

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Retrieved on: 
Saturday, February 17, 2024
Biotechnology, Infectious Diseases, Health, Clinical Trials, Oncology, MPH, Virology, Multimedia, Neurology

Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.

Key Points: 
  • Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.
  • This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, and neurology.
  • “This event not only reconfirmed company’s growth strategy but also reinforced our commitment to our mission.
  • As we embark on this new chapter, we look forward to contributing to the market's vibrancy and delivering value to our shareholders and patients.”

Tevogen Bio Announces $8 Million Equity Investment

Retrieved on: 
Thursday, February 15, 2024
Oncology, Health, Infectious Diseases, Health Insurance, Clinical Trials, Biotechnology, Therapy, Virology, Neurology, Security (finance)

On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.

Key Points: 
  • On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.
  • “We are excited to begin our journey as a public company with this additional investment,” said Dr. Ryan Saadi, the Company’s Chief Executive Officer and Chairperson.
  • “We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare.
  • The Series A Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year.

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Retrieved on: 
Thursday, February 15, 2024
Arbutus, Virology, CFBV, Conference, Broadcasting

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.

Key Points: 
  • WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.
  • The schedule for the press release and conference call/webcast are as follows:
    Q4 and Year End 2023 Press Release:
    Q4 and Year End 2023 Conference Call/Webcast:
    To dial-in for the conference call by phone, please register using the following link: Registration Link .
  • A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com .
  • An archived webcast will be available on the Arbutus website after the event.

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Virology, Health, Cancer, Chairperson, Antigen, DSM-IV codes, Infection, TVGN, Neurology

Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Key Points: 
  • Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.
  • WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.
  • The combined company’s common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.
  • The listing with Nasdaq is expected to provide Tevogen Bio increased access to capital to accelerate the development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Wednesday, February 7, 2024
COVID-19, Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, B cell, Chronic obstructive pulmonary disease, Pharmacokinetics, KIT, HCV, Patient, Safety, Heart, Drug discovery, Virology, Fiscal, Disease, CSU, ADME, RSV, Sale, OMERS, Viral load, Medication, Asthma, Conference, Pharmaceutical industry

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.
  • “In 2024, Enanta began a year which will be marked by execution and value creation across the company.
  • For the three months ended December 31, 2022, total revenue was $23.6 million and was primarily related to royalties on AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Interest expense from the royalty sale was $3.4 million for the three months ended December 31, 2023.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Virology, Immunology, Webcast, Medication, Conference

Enanta Pharmaceuticals, Inc .

Key Points: 
  • Enanta Pharmaceuticals, Inc .
  • (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 11:20 a.m.
  • A live webcast of the event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for at least 30 days.

Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus

Retrieved on: 
Wednesday, January 31, 2024
Infectious Diseases, Pharmaceutical, Health, Oncology, Therapy, Virology, Medicine, Neurology, Semper paratus

Tevogen Bio Inc (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation.

Key Points: 
  • Tevogen Bio Inc (“Tevogen Bio”) is looking forward to and continues to work toward the anticipated closing of its proposed business combination with Semper Paratus Acquisition Corporation.
  • “Tevogen Bio’s business combination with Semper Paratus can help us achieve our goal to become the first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, and we look forward to investors having the opportunity to join us in this mission,” said Ryan Saadi, Chief Executive Officer of Tevogen Bio.
  • “We believe that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.”